


CLAIMS

1. A pharmaceutical composition for the treatment of anxiety or depression in a mammal, comprising: (a) a compound that exhibits activity, respectively, as an anxiolytic agent or an antidepressant, or a pharmaceutically acceptable salt thereof; (b) a CNS-penetrant NK-1 receptor antagonist or pharmaceutically acceptable salt thereof; and (c) a pharmaceutically acceptable carrier; wherein the active agents "a" and "b" above are present in amounts that render the composition effective in treating, respectively, anxiety or depression.


2. A pharmaceutical composition according to ~~claim~~ 1, wherein the NK-1 receptor antagonist or pharmaceutically acceptable salt thereof is selected from compounds of the formula I, as defined below, and their pharmaceutically acceptable salts:




wherein X¹ is hydrogen, (C₁-C₁₀) alkoxy optionally substituted with from one to three fluorine atoms or (C₁-C₁₀) alkyl optionally substituted with from one to three fluorine atoms;

X² and X³ are independently selected from hydrogen, halo, nitro, (C₁-C₁₀) alkyl optionally substituted with from one to three fluorine atoms, (C₁-C₁₀) alkoxy optionally substituted with from one to three fluorine atoms, trifluoromethyl, hydroxy, phenyl, cyano, amino, (C₁-C₆)-alkylamino, di-(C₁-C₆)alkylamino, -C(=O)-NH-(C₁-C₆)alkyl, (C₁-C₆) alkyl-C(=O)-NH-(C₁-C₆) alkyl, hydroxy(C₁-C₄)alkyl, (C₁-C₄)alkoxy(C₁-C₄)alkyl, -NHC(=O)H and -NHC(=O)-(C₁-C₆) alkyl; and


Q is a group of the formula




II




III




IV



V




VI



VII

OR



VIII


wherein R^1 is a radical selected from furyl, thienyl, pyridyl, indolyl, biphenyl and phenyl optionally substituted with one or two substituents independently selected from halo, (C_1-C_{10}) alkyl optionally substituted with from one to three fluorine atoms, (C_1-C_{10}) alkoxy optionally substituted with from one to three fluorine atoms, carboxy, benzyloxycarbonyl and (C_1-C_3) alkoxy-carbonyl;

5 R^{13} is selected from (C_3-C_4) branched alkyl, (C_5-C_6) branched alkenyl, (C_5-C_7) cycloalkyl, and the radicals named in the definition of R^1 ;

R^2 is hydrogen or (C_1-C_6) alkyl;

R^3 is phenyl, biphenyl, naphthyl, pyridyl, benzhydryl, thienyl or furyl, and R^3 may optionally be substituted with from one to three substituents independently selected from halo, (C_1-C_{10}) alkyl optionally substituted with from one to three fluorine atoms and (C_1-C_{10}) alkoxy optionally substituted with from one to three fluorine atoms;

Y is $(CH_2)_l$ wherein l is an integer from one to three, or Y is a group of the formula



Z is oxygen, sulfur, amino, (C_1-C_3) alkylamino or $(CH_2)_n$ wherein n is zero, one or two;

15 o is two or three;

p is zero or one;

R^4 is furyl, thienyl, pyridyl, indolyl, biphenyl, or phenyl optionally substituted with one or two substituents independently selected from halo, (C_1-C_{10}) alkyl optionally substituted with from one to three fluorine atoms, (C_1-C_{10}) alkoxy optionally substituted with from one to three fluorine atoms, carboxy, (C_1-C_3) alkoxy-carbonyl and benzyloxycarbonyl;

20 R^5 is thienyl, biphenyl or phenyl optionally substituted with one or two substituents independently selected from halo, (C_1-C_{10}) alkyl optionally substituted with from one to three fluorine atoms and (C_1-C_{10}) alkoxy optionally substituted with from one to three fluorine atoms;

25 X is $(CH_2)_q$ wherein q is an integer from 1 to 6, and wherein any one of the carbon-carbon single bonds in said $(CH_2)_q$ may optionally be replaced by a carbon-carbon double bond, and wherein any one of the carbon atoms of said $(CH_2)_q$ may optionally be substituted with R^8 , and wherein any one of the carbon atoms of said $(CH_2)_q$ may optionally be substituted with R^9 ;

30 m is an integer from 0 to 8, and any one of the carbon-carbon single bonds of $(CH_2)_m$ may optionally be replaced by a carbon-carbon double bond or a carbon-carbon triple bond, and any one of the carbon atoms of said $(CH_2)_m$ may optionally be substituted with R^{11} ;

R^6 is a radical selected from hydrogen, (C_1-C_6) straight or branched alkyl, (C_3-C_7) cycloalkyl wherein one of the carbon atoms may optionally be replaced by nitrogen, oxygen or sulfur; aryl selected from biphenyl, phenyl, indanyl and naphthyl; heteroaryl selected from thienyl,

furyl, pyridyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl, tetrazolyl and quinolyl; phenyl (C₂-C₆) alkyl, benzhydryl and benzyl, wherein each of said aryl and heteroaryl groups and the phenyl moieties of said benzyl, phenyl (C₂-C₆) alkyl and benzhydryl may optionally be substituted with one or more substituents independently selected from halo, nitro, (C₁-C₁₀) alkyl optionally substituted with from one to three fluorine atoms, (C₁-C₁₀) alkoxy optionally substituted with from one to three fluorine atoms, amino, hydroxy-(C₁-C₆)alkyl, (C₁-C₆)alkoxy-(C₁-C₆)alkyl, (C₁-C₆)-alkylamino, (C₁-C₆)alkyl-O-C(=O)-, (C₁-C₆) alkyl-O-C(=O)-(C₁-C₆)alkyl, (C₁-C₆)alkyl-C(=O)-O-, (C₁-C₆)alkyl-C(=O)-(C₁-C₆)alkyl-O-, (C₁-C₆)alkyl-C(=O)-, (C₁-C₆)alkyl-C(=O)-(C₁-C₆)alkyl-, di-(C₁-C₆)alkylamino, -C(=O)NH-(C₁-C₆)alkyl, (C₁-C₆)-alkyl-C(=O)-NH-(C₁-C₆)alkyl, -NHC(=O)H and -NHC(=O)-(C₁-C₆) alkyl; and wherein one of the phenyl moieties of said benzhydryl may optionally be replaced by naphthyl, thienyl, furyl or pyridyl;

R⁷ is hydrogen, phenyl or (C₁-C₆)alkyl;

or R⁶ and R⁷, together with the carbon to which they are attached, form a saturated carbocyclic ring having from 3 to 7 carbon atoms wherein one of said carbon atoms may optionally be replaced by oxygen, nitrogen or sulfur;

R⁸ and R⁹ are each independently selected from hydrogen, hydroxy, halo, amino, oxo (=O), nitrile, hydroxy-(C₁-C₆)alkyl, (C₁-C₆)alkoxy-(C₁-C₆)alkyl, (C₁-C₆)alkylamino, di-(C₁-C₆)alkylamino, (C₁-C₆)alkoxy, (C₁-C₆)alkyl-O-C(=O)-, (C₁-C₆)alkyl-O-C(=O)-(C₁-C₆)alkyl-, (C₁-C₆)alkyl-C(=O)-O-, (C₁-C₆)alkyl-C(=O)-(C₁-C₆)alkyl-O-, (C₁-C₆)alkyl-C(=O)-, (C₁-C₆)alkyl-C(=O)-(C₁-C₆)alkyl-, and the radicals set forth in the definition of R⁶;


R¹⁰ is NHCR¹², NHCH₂R¹², NHSO₂R¹² or one of the radicals set forth in any of the definitions of R⁶, R⁸ and R⁹;

R¹¹ is oximino (=NOH) or one of the radicals set forth in any of the definitions of R⁶, R⁸ and R⁹; and


R¹² is (C₁-C₆)alkyl, hydrogen, phenyl(C₁-C₆)alkyl or phenyl optionally substituted with (C₁-C₆) alkyl; and

with the proviso that (a) when m is 0, R¹¹ is absent, (b) neither R⁸, R⁹, R¹⁰ nor R¹¹ can form, together with the carbon to which it is attached, a ring with R⁷, (c) when Q is a group of the formula VIII, R⁸ and R⁹ cannot be attached to the same carbon atom, and (d) when R⁸ and R⁹ are attached to the same carbon atom, then either each of R⁸ and R⁹ is independently selected from hydrogen, fluoro, (C₁-C₆) alkyl, hydroxy-(C₁-C₆)alkyl and (C₁-C₆)alkoxy-(C₁-C₆)alkyl, or R⁸ and R⁹, together with the carbon to which they are attached, form a (C₃-C₆) saturated carbocyclic ring that forms a spiro compound with the nitrogen-containing ring to which they are attached.

3. A pharmaceutical composition according to claim 1, wherein the NK-1 receptor antagonist or pharmaceutically acceptable salt thereof is selected from compounds of the formula IXa or IXb, as defined below, and their pharmaceutically acceptable salts:



or



and their pharmaceutically acceptable salts, wherein A is a ring system selected from phenyl, naphthyl, thienyl, quinoliny and indoliny, and wherein the side chain containing NR^2R^3 is attached to a carbon atom of ring system A;

W is hydrogen, $(\text{C}_1\text{-C}_6)\text{alkyl}$ optionally substituted with from one to three fluorine atoms, $\text{S}(\text{O})_v\text{-(C}_1\text{-C}_6)\text{ alkyl}$ wherein v is zero, one or two, halo, benzyloxy or $(\text{C}_1\text{-C}_6)\text{alkoxy}$ optionally substituted with from one to three fluorine atoms;

R^1 is a 4, 5 or 6 membered heterocyclic ring containing from one to three heteroatoms selected from oxygen, nitrogen and sulfur (e.g., thiazolyl, azetidiny, pyrrolyl, pyrazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, isothiazolyl, imidazolyl, isoxazolyl, oxazolyl, pyridyl, pyrimidiny, pyrazolyl or thiophenyl), wherein said heterocyclic ring may contain from zero to three double bonds and may optionally be substituted with one or more substituents, preferably one or two substituents, independently selected from $(\text{C}_1\text{-C}_6)\text{ alkyl}$ optionally substituted with from one to three fluorine atoms and $(\text{C}_1\text{-C}_6)\text{ alkoxy}$ optionally substituted with from one to three fluorine atoms;

the dotted lines in formula Ib indicate that one of the X'-Y' and Y'-Z' bonds may optionally be a double bond;

X' is selected from $=\text{CH-}$, $-\text{CH}_2\text{-}$, $-\text{O-}$, $-\text{S-}$, $-\text{SO-}$, $-\text{SO}_2\text{-}$, $-\text{N}(\text{R}^4)\text{-}$, $-\text{NH-}$, $=\text{N-}$, $-\text{CH}[(\text{C}_1\text{-C}_6)\text{alkyl}]$ -, $=\text{C}[(\text{C}_1\text{-C}_6)\text{alkyl}]$ -, $-\text{CH}(\text{C}_6\text{H}_5)\text{-}$ and $=\text{C}(\text{C}_6\text{H}_5)\text{-}$;

Y' is selected from $\text{C}=\text{O}$, $\text{C}=\text{NR}^4$, $\text{C}=\text{S}$, $=\text{CH-}$, $-\text{CH}_2\text{-}$, $=\text{C}[(\text{C}_1\text{-C}_6)\text{alkyl}]$ -, $-\text{CH}[(\text{C}_1\text{-C}_6)\text{alkyl}]$ -, $=\text{C}(\text{C}_6\text{H}_5)\text{-}$, $-\text{CH}(\text{C}_6\text{H}_5)\text{-}$, $=\text{N-}$, $-\text{NH-}$, $-\text{N}(\text{R}^4)\text{-}$, $=\text{C}(\text{halo})\text{-}$, $=\text{C}(\text{OR}^4)\text{-}$, $=\text{C}(\text{SR}^4)\text{-}$, $=\text{C}(\text{NR}^4)\text{-}$, $-\text{O-}$, $=\text{C}(\text{CF}_3)\text{-}$, $=\text{C}(\text{CH}_2\text{C}_6\text{H}_5)\text{-}$, $-\text{S-}$ and SO_2 , wherein the phenyl moieties of said $=\text{C}(\text{C}_6\text{H}_5)\text{-}$ and $-\text{CH}(\text{C}_6\text{H}_5)\text{-}$ may optionally be substituted with from one to three substituents independently selected from trifluoromethyl and halo, and wherein the alkyl moieties of said $=[(\text{C}_1\text{-C}_6)\text{alkyl}]$ - and $-\text{CH}[(\text{C}_1\text{-C}_6)\text{alkyl}]$ - may optionally be substituted with from one to three fluorine atoms;


Z' is selected from $=\text{CH-}$, $-\text{CH}_2\text{-}$, $=\text{N-}$, $-\text{NH-}$, $-\text{S-}$, $-\text{N}(\text{R}^4)\text{-}$, $=\text{C}(\text{C}_6\text{H}_5)\text{-}$, $-\text{CH}(\text{C}_6\text{H}_5)\text{-}$, $=\text{C}[(\text{C}_1\text{-C}_6)\text{ alkyl}]$ - and $-\text{CH}[(\text{C}_1\text{-C}_6)\text{alkyl}]$ -;

or X', Y' and Z', together with the two carbon atoms shared between the benzo ring and the X'Y'Z' ring, form a fused pyridine or pyrimidine ring;


R² is hydrogen or -CO₂(C₁-C₁₀)alkyl;

R³ is selected from


00204 022060




V




XI




XII




XIII



XIV




XV



XVI

and



XVII

wherein R^6 and R^{10} are independently selected from furyl, thienyl, pyridyl, indolyl, biphenyl and phenyl, wherein said phenyl may optionally be substituted with one or two substituents independently selected from halo, (C_1-C_{10}) alkyl optionally substituted with from one to three fluorine atoms, (C_1-C_{10}) alkoxy optionally substituted with from one to three fluorine atoms, carboxy, benzyloxycarbonyl and (C_1-C_3) alkoxy-carbonyl;


R^4 is (C_1-C_6) alkyl or phenyl;

R^7 is selected from (C_3-C_4) branched alkyl, (C_5-C_6) branched alkenyl, (C_5-C_7) cycloalkyl, and the radicals named in the definition of R^6 ;

R^8 is hydrogen or (C_1-C_6) alkyl;

R^9 and R^{19} are independently selected from phenyl, biphenyl, naphthyl, pyridyl, benzhydryl, thienyl and furyl, and R^9 and R^{19} may optionally be substituted with from one to three substituents independently selected from halo, (C_1-C_{10}) alkyl optionally substituted with from one to three fluorine atoms and (C_1-C_{10}) alkoxy optionally substituted with from one to three fluorine atoms;

Y is $(CH_2)_l$ wherein l is an integer from one to three, or Y is a group of the formula



Z is oxygen, sulfur, amino, (C_1-C_3) alkylamino or $(CH_2)_n$ wherein n is zero, one or two;

x is zero, one or two;

y is zero, one or two;

z is three, four or five;

o is two or three;

p is zero or one;

r is one, two or three;

the ring containing $(CH_2)_z$ may contain from zero to three double bonds, and one of the carbon atoms of $(CH_2)_z$ may optionally be replaced by oxygen, sulfur or nitrogen;

R^{11} is thienyl, biphenyl or phenyl optionally substituted with one or two substituents independently selected from halo, (C_1-C_{10}) alkyl optionally substituted with from one to three fluorine atoms and (C_1-C_{10}) alkoxy optionally substituted with from one to three fluorine atoms;

X is $(CH_2)_q$ wherein q is an integer from 1 to 6, and wherein any one of the carbon-carbon single bonds in said $(CH_2)_q$ may optionally be replaced by a carbon-carbon double bond, and wherein any one of the carbon atoms of said $(CH_2)_q$ may optionally be substituted with R^{14} , and wherein any one of the carbon atoms of said $(CH_2)_q$ may optionally be substituted with R^{15} ;

m is an integer from 0 to 8, and any one of the carbon-carbon single bonds of $(CH_2)_m$, wherein both carbon atoms of such bond are bonded to each other and to another carbon atom of the $(CH_2)_m$ chain, may optionally be replaced by a carbon-carbon double bond or a carbon-carbon triple bond, and any one of the carbon atoms of said $(CH_2)_m$ may optionally be substituted with R^{17} ;

R^{12} is a radical selected from hydrogen, (C_1-C_6) straight or branched alkyl, (C_3-C_7) cycloalkyl wherein one of the carbon atoms may optionally be replaced by nitrogen, oxygen or sulfur; aryl selected from biphenyl, phenyl, indanyl and naphthyl; heteroaryl selected from thienyl, furyl, pyridyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl, tetrazolyl and quinolyl; phenyl- (C_2-C_6) alkyl, benzhydryl and benzyl, wherein the point of attachment on R^{12} is a carbon atom unless R^{12} is hydrogen, and wherein each of said aryl and heteroaryl groups and the phenyl moieties of said benzyl, phenyl- (C_2-C_6) alkyl and benzhydryl may optionally be substituted with one or more substituents independently selected from halo, nitro, (C_1-C_{10}) alkyl optionally substituted with from one to three fluorine atoms, (C_1-C_{10}) alkoxy optionally substituted with from one to three fluorine atoms, amino, hydroxy- (C_1-C_6) alkyl, (C_1-C_6) alkoxy- (C_1-C_6) alkyl, (C_1-C_6) -alkylamino, (C_1-C_6) alkyl-O-C(=O)-, (C_1-C_6) alkyl-O-C(=O)-(C₁-C₆)alkyl, (C_1-C_6) alkyl-C(=O)-O-, (C_1-C_6) alkyl-C(=O)-(C₁-C₆)alkyl-O-, (C_1-C_6) alkyl-C(=O)-, (C_1-C_6) alkyl-, di- (C_1-C_6) alkylamino, -C(=O)-NH-(C₁-C₆)alkyl, (C_1-C_6) -alkyl-C(=O)-NH-(C₁-C₆)alkyl, -NHC(=O)H and -NHC(=O)-(C₁-C₆)alkyl; and wherein one of the phenyl moieties of said benzhydryl may optionally be replaced by naphthyl, thienyl, furyl or pyridyl;

R^{13} is hydrogen, phenyl or (C_1-C_6) alkyl;

or R^{12} and R^{13} , together with the carbon to which they are attached, form a saturated carbocyclic ring having from 3 to 7 carbon atoms wherein one of said carbon atoms that is neither the point of attachment of the spiro ring nor adjacent to such point of attachment may optionally be replaced by oxygen, nitrogen or sulfur;

R^{14} and R^{15} are each independently selected from hydrogen, hydroxy, halo, amino, oxo (=O), cyano, hydroxy- (C_1-C_6) alkyl, (C_1-C_6) alkoxy- (C_1-C_6) alkyl, (C_1-C_6) alkylamino, di- (C_1-C_6) alkylamino, (C_1-C_6) alkoxy, -C(=O)-OH, (C_1-C_6) alkyl-O-C(=O)-, (C_1-C_6) alkyl-O-C(=O)-(C₁-C₆)alkyl, (C_1-C_6) alkyl-C(=O)-O-, (C_1-C_6) alkyl-C-(C₁-C₆)alkyl-O-, (C_1-C_6) alkyl-C(=O)-, (C_1-C_6) alkyl-C(=O)-(C₁-C₆)alkyl-, and the radicals set forth in the definition of R^{12} ;

R^{16} is $NHC(=O)R^{18}$, $NHCH_2R^{18}$, SO_2R^{18} , CO_2H or one of the radicals set forth in any of the definitions of R^{12} , R^{14} and R^{15} ;


R^{17} is oximino (=NOH) or one of the radicals set forth in any of the definitions of R^{12} , R^{14} and R^{15} ; and

R^{18} is (C_1-C_6) alkyl, hydrogen, phenyl or phenyl (C_1-C_6) alkyl;

with the proviso that (a) when m is 0, one of R^{16} and R^{17} is absent and the other is hydrogen, (b) when R^3 is a group of the formula XVI, R^{14} and R^{15} cannot be attached to the same

carbon atom, (c) when R^{14} and R^{15} are attached to the same carbon atom, then either each of R^{14} and R^{15} is independently selected from hydrogen, fluoro, (C_1-C_6) alkyl, hydroxy- (C_1-C_6) alkyl and (C_1-C_6) alkoxy- (C_1-C_6) alkyl, or R^{14} and R^{15} , together with the carbon to which they are attached, form a (C_3-C_6) saturated carbocyclic ring that forms a spiro compound with the nitrogen-containing ring to which they are attached; (d) R^{12} and R^{13} can not both be hydrogen, and (e) when R^{14} or R^{15} is attached to a carbon atom of X or $(CH_2)_y$ that is adjacent to the ring nitrogen, then R^{14} or R^{15} , respectively, must be a substituent wherein the point of attachment is a carbon atom.

4. A pharmaceutical composition according to claim 1, wherein the NK-1 receptor antagonist or pharmaceutically acceptable salt thereof is selected from compounds of the formula XVIII, as depicted and defined below, and their pharmaceutically acceptable salts:




wherein R is halo (C_1-C_8) alkyl, halo (C_2-C_8) alkenyl, halo (C_2-C_8) alkynyl or halo (C_1-C_8) alkyl substituted by hydroxy or (C_1-C_8) alkoxy; R^1 is hydrogen, halo or (C_1-C_6) alkoxy; or

- 15 R and R^1 , together with the two carbon atoms shared between the benzene ring and the R and R^1 , complete a fused (C_4-C_6) cycloalkyl wherein one carbon atom is optionally replaced by oxygen and wherein one or two of the carbon atoms are optionally substituted by up to five substituents selected from halo, (C_1-C_6) alkyl and halo (C_1-C_6) alkyl;

X is (C_1-C_6) alkoxy, halo (C_1-C_6) alkoxy, phenoxy or halo; and

- 20 Ar is phenyl optionally substituted by halo.

5. A pharmaceutical composition according to claim 1, wherein the NK-1 receptor antagonist or pharmaceutically acceptable salt thereof is selected from compounds of the formula XIX, as depicted and defined below, and their pharmaceutically acceptable salts:



wherein

W is methylene, ethylene, propylene, vinylene, $-\text{CH}_2\text{-O-}$, $-\text{O-CH}_2\text{-}$, $-\text{CH}_2\text{-S-}$ or $-\text{S-CH}_2\text{-}$;

R^1 , R^2 and R^3 are independently hydrogen, $(\text{C}_1\text{-C}_3)$ alkyl, $(\text{C}_1\text{-C}_3)$ alkoxy or halo $(\text{C}_1\text{-C}_3)$ alkyl, provided that when W is methylene, both R^2 and R^3 are not hydrogen;


5 X is halo, $(\text{C}_1\text{-C}_3)$ alkoxy, $(\text{C}_1\text{-C}_3)$ alkoxy or $(\text{C}_1\text{-C}_3)$ alkenyl;

Y is imino or oxy;

Q is oxygen or sulfur; and

T is (2S,3S)-2-diphenylmethylquinuclidin-3-yl, (2S,3S)-2-phenylpiperdin-3-yl or (2S,3S)-2-diphenylmethyl-1-azanorbornan-3-yl.


10 6. A pharmaceutical composition according to claim 1, wherein the NK-1 receptor antagonist or pharmaceutically acceptable salt thereof is selected from compounds of the formula XX, as depicted and defined below, and their pharmaceutically acceptable salts:



wherein R^1 is phenyl optionally substituted with one or more substituents, preferably with
 15 from one to three substituents, independently selected from hydrogen, halo, nitro, $(\text{C}_1\text{-C}_{10})$ alkyl optionally substituted with from one to three fluorine atoms, $(\text{C}_1\text{-C}_{10})$ alkoxy optionally substituted with from one to three fluorine atoms, trifluoromethyl, hydroxy, phenyl, cyano, amino, $(\text{C}_1\text{-C}_6)$ -alkylamino, di- $(\text{C}_1\text{-C}_6)$ -alkylamino, $-\text{C}(=\text{O})\text{-NH-}(\text{C}_1\text{-C}_6)\text{alkyl}$, $(\text{C}_1\text{-C}_6)\text{alkyl-C}(=\text{O})\text{-NH-}(\text{C}_1\text{-C}_6)$ alkyl, hydroxy $(\text{C}_1\text{-C}_4)\text{alkyl-NHC}(=\text{O})\text{H}$, $-\text{NHC}(=\text{O})\text{-(C}_1\text{-C}_6)$ alkyl, $(\text{C}_1\text{-C}_4)\text{alkoxy(C}_1\text{-C}_4)\text{alkyl}$, -
 20 $\text{S(O)}_v\text{-(C}_1\text{-C}_{10})\text{-alkyl}$ wherein v is zero, one or two, $-\text{S(O)}_v\text{-aryl}$ wherein v is zero, one or two, -O-aryl, $-\text{SO}_2\text{NR}^4\text{R}^5$ wherein each of R^4 and R^5 is, independently, $(\text{C}_1\text{-C}_6)\text{alkyl}$, or R^4 and R^5 , together with the nitrogen to which they are attached, form a saturated ring containing one nitrogen and from 3 to 6 carbons, $(\text{SO}_2\text{-(C}_1\text{-C}_{10})\text{alkyl}) ((\text{C}_1\text{-C}_{10})\text{alkyl})\text{N}$ wherein one or both of the alkyl moieties may optionally be substituted with from one to three fluorine atoms, $-\text{N}(\text{SO}_2\text{-(C}_1\text{-C}_{10})\text{alkyl})_2$ and $(\text{SO}_2\text{-aryl}) ((\text{C}_1\text{-C}_{10})\text{alkyl})\text{N}$; and wherein the aryl moieties of said $-\text{S(O)}_v\text{-aryl}$, -O-aryl and $(\text{SO}_2\text{-aryl}) ((\text{C}_1\text{-C}_{10})\text{alkyl})\text{N}$ are independently selected from phenyl and benzyl and may
 25

optionally be substituted with from one to three substituents independently selected from (C₁-C₄)alkyl, (C₁-C₄)alkoxy and halo;

or R¹ is phenyl substituted with a group having the formula



5 wherein a is 0, 1 or 2 and the asterisk represents a position meta to the point of attachment of R¹;

R² is selected from (C₁-C₆) straight or branched alkyl, (C₃-C₇) cycloalkyl wherein one of the carbon atoms may optionally be replaced by nitrogen, oxygen or sulfur; aryl selected from biphenyl, phenyl, indanyl and naphthyl; heteroaryl selected from thienyl, furyl, pyridyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl, tetrazolyl and quinolyl; phenyl (C₂-C₆) alkyl, benzhydryl and benzyl, wherein each of said aryl and heteroaryl groups and the phenyl moieties of said benzyl, phenyl (C₂-C₆) alkyl and benzhydryl may optionally be substituted with one or more substituents, preferably with from one to three substituents, independently selected from halo, nitro, (C₁-C₁₀) alkyl optionally substituted with from one to three fluorine atoms, (C₁-C₁₀) alkoxy optionally substituted with from one to three fluorine atoms, amino, hydroxy-(C₁-C₆)alkyl, (C₁-C₆)alkoxy-(C₁-C₆)alkyl, (C₁-C₆)-alkylamino, (C₁-C₆)alkyl-O-C(=O)-, (C₁-C₆)alkyl-O-C(=O)-(C₁-C₆)alkyl, (C₁-C₆)alkyl-C(=O)-O-, (C₁-C₆)alkyl-C-(C₁-C₆)alkyl-O-, (C₁-C₆)alkyl-C(=O)-, (C₁-C₆)alkyl-C-(C₁-C₆)alkyl-, di-(C₁-C₆)alkylamino, -C(=O)NH-(C₁-C₆)alkyl, (C₁-C₆)-alkyl-C(=O)-NH-(C₁-C₆)alkyl, -NHC(=O)H and -NHC(=O)-(C₁-C₆) alkyl; and wherein one of the phenyl moieties of said benzhydryl may optionally be replaced by naphthyl, thienyl, furyl or pyridyl;

m is an integer from 0 to 8, and any one of the carbon-carbon single bonds of (CH₂)_m, wherein both carbon atoms of such bond are bonded to each other and to another carbon atom in the (CH₂)_m chain, may optionally be replaced by a carbon-carbon double bond or a carbon-carbon triple bond, and any one of the carbon atoms of said (CH₂)_m may optionally be substituted with R⁴;

R³ is selected from NHC(=O)R⁸, NHCH₂R⁸, SO₂R⁸, AR⁵, CO₂H and the radicals set forth in the definitions of R², R⁶ and R⁷;


A is CH₂, nitrogen, oxygen, sulfur or carbonyl;

30 R⁸ is (C₁-C₆)alkyl, hydrogen, phenyl or phenyl (C₁-C₆)alkyl;

R⁴ is selected from oximino (=NOH) and the radicals set forth in the definitions of R², R⁶ and R⁷;

R⁵ is a monocyclic or bicyclic heterocycle selected from the group consisting of pyrimidinyl, benzoxazolyl, 2,3-dihydro-3-oxobenzisulfonazol-2-yl, morpholin-1-yl,

thiomorpholin-1-yl, benzofuranyl, benzothienyl, indolyl, isoindolyl, isoquinolyl, furyl, pyridyl, isothiazolyl, oxazolyl, triazolyl, tetrazolyl, quinolyl, thiazolyl, thienyl, and groups of the formulae



- wherein B and D are selected from carbon, oxygen and nitrogen, and at least one of B and D is other than carbon; E is carbon or nitrogen; n is an integer from 1 to 5; any one of the carbon atoms of said $(CH_2)_n$ and $(CH_2)_{n+1}$ may be optionally substituted with (C_1-C_6) alkyl or (C_2-C_6) spiroalkyl; and either any one pair of the carbon atoms of said $(CH_2)_n$ and $(CH_2)_{n+1}$ may be bridged by a one or two carbon atom linkage, or any one pair of adjacent carbon atoms of said $(CH_2)_n$ and $(CH_2)_{n+1}$ may form, together with from one to three carbon atoms that are not members of the carbonyl containing ring, a (C_3-C_5) fused carbocyclic ring;


X is $(CH_2)_q$ wherein q is two or three and wherein one of the carbon-carbon single bonds in said $(CH_2)_q$ may optionally be replaced by a carbon-carbon double bond, and wherein any one of the carbon atoms of said $(CH_2)_q$ may optionally be substituted with R^6 , and wherein any one of the carbon atoms of said $(CH_2)_q$ may optionally be substituted with R^7 ;

- R^6 and R^7 are independently selected from hydrogen, hydroxy, halo, amino, oxo ($=O$), cyano, hydroxy- (C_1-C_6) alkyl, (C_1-C_6) alkoxy- (C_1-C_6) alkyl, (C_1-C_6) alkylamino, di- (C_1-C_6) alkylamino, (C_1-C_6) alkoxy, $-C(=O)-OH$, (C_1-C_6) alkyl-O- $C(=O)-$, (C_1-C_6) alkyl-O- $C(=O)-(C_1-C_6)$ alkyl, (C_1-C_6) alkyl-C($=O$)-O-, (C_1-C_6) alkyl-C($=O$)-(C- C_6)alkyl-O-, (C_1-C_6) alkyl-C-, (C_1-C_6) alkyl-C($=O$)-(C- C_6)alkyl- and the radicals set forth in the definition of R^2 ; and

- Y is $(CH_2)_z$ wherein z is zero or one;

- with the proviso that: (a) when A is $-(CH_2)-$ or carbonyl, R^5 cannot be furyl, pyridyl, isothiazolyl, oxazolyl, triazolyl, tetrazolyl, quinolyl, thiazolyl or thienyl; (b) when m is zero, one of R^3 and R^4 is absent and the other is hydrogen; (c) when R^6 or R^7 is attached to a carbon atom of X that is adjacent to the ring nitrogen, then R^6 or R^7 , respectively, must be a substituent wherein the point of attachment is a carbon atom;

7. A pharmaceutical composition according to claim 1, wherein the NK-1 receptor antagonist or pharmaceutically acceptable salt thereof is selected from compounds of the formula XXI, as depicted and defined below, and their pharmaceutically acceptable salts:



wherein R¹ is selected from hydrogen, (C₁-C₆) straight or branched alkyl, (C₃-C₇) cycloalkyl wherein one of the carbon atoms may optionally be replaced by nitrogen, oxygen or sulfur; aryl selected from phenyl, biphenyl, indanyl and naphthyl; heteroaryl selected from thienyl, furyl, pyridyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl, tetrazolyl and quinolyl; phenyl (C₂-C₆) alkyl, benzhydryl and benzyl, wherein each of said aryl and heteroaryl groups and the phenyl moieties of said benzyl, phenyl (C₂-C₆) alkyl and benzhydryl may optionally be substituted with one or more substituents independently selected from halo, nitro, (C₁-C₆) alkyl optionally substituted with from one to three fluorine atoms, (C₁-C₆) alkoxy, amino, trihaloalkoxy (e.g., trifluoromethoxy), (C₁-C₆)alkylamino, (C₁-C₆)alkyl-O-C(=O)-, (C₁-C₆)alkyl-O-C(=O)- (C₁-C₆)alkyl, (C₁-C₆)alkyl-C(=O)-O-, (C₁-C₆)alkyl-C-, (C₁-C₆)alkyl-O-, (C₁-C₆)alkyl-C(=O)-, (C₁-C₆)alkyl-C(=O)-, (C₁-C₆)alkyl-, di-(C₁-C₆)alkylamino, -C(=O)NH-(C₁-C₆)alkyl, (C₁-C₆)alkyl-C(=O)-NH-(C₁-C₆)alkyl-, -NHC(=O)H and -NHC(=O)-(C₁-C₆) alkyl; and wherein one of the phenyl moieties of said benzhydryl may optionally be replaced by naphthyl, thienyl, furyl or pyridyl;

R³ is aryl selected from phenyl and naphthyl; heteroaryl selected from indanyl, thienyl, furyl, pyridyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl, tetrazolyl and quinolyl; and cycloalkyl having 3 to 7 carbon atoms wherein one of said carbon atoms may optionally be replaced by nitrogen, oxygen or sulfur; wherein each of said aryl and heteroaryl groups may optionally be substituted with one or more substituents, and said (C₃-C₇) cycloalkyl may optionally be substituted with one or two substituents, each of said substituents being independently selected from halo, nitro, (C₁-C₆) alkyl optionally substituted with from one to three fluorine atoms, (C₁-C₆) alkoxy, amino, phenyl, trihaloalkoxy (e.g., trifluoromethoxy), (C₁-C₆) alkylamino, -C(=O)-NH-(C₁-C₆)alkyl, (C₁-C₆)alkyl-C(=O)- -C-O-(C₁-C₆)alkyl, -C(=O)H, -CH₂OR¹³, NH(C₁-C₆)alkyl-, -NHC(=O)H, -NR²⁴C-(C₁-C₆)alkyl and -NHC(=O)-(C₁-C₆)alkyl;


one of R⁵ and R⁶ is hydrogen and the other is selected from hydroxymethyl, hydrogen, (C₁-C₃)alkyl, (C₁-C₈)acyloxy(C₁-C₃)alkyl, (C₁-C₈)alkoxymethyl and benzyloxymethyl;

R⁷ and R⁸ are independently selected from hydrogen, (C₁-C₃)alkyl and phenyl;

R⁹ is selected from methyl, hydroxymethyl, HC(=O)-, R¹⁴R¹⁵NCO₂CH₂-, R¹⁶OCO₂CH₂-, (C₁-C₄)alkyl-CO₂CH₂-, -CONR¹⁷R¹⁸, R¹⁷R¹⁸NCO₂-, R¹⁹OCO₂-, C₆H₅CH₂CO₂CH₂-, C₆H₅CO₂CH₂-, (C₁-C₄)alkyl-CH(OH)-, C₆H₅CH(OH)-, C₆H₅CH₂CH(OH)-, CH₂halo, R²⁰SO₂OCH₂-, -CO₂R¹⁶ and R²¹CO₂-;

R¹⁰ and R¹¹ are independently selected from hydrogen, (C₁-C₃) alkyl and phenyl;

R¹² is hydrogen, benzyl or a group of the formula



wherein m is an integer from zero to twelve, and any one of the carbon-carbon single bonds of (CH₂)_m may optionally be replaced by a carbon-carbon double or triple bond, and any

one of the carbon atoms of $(CH_2)_m$ may optionally be substituted with R^{23} (as indicated by the slanted line to R^{23} which intersects the horizontal line to $(CH_2)_m$ in the above figure);

R^{13} , R^{14} , R^{15} , R^{16} , R^{17} , R^{18} , R^{19} , R^{20} , R^{21} and R^{24} are independently selected from hydrogen, (C_1-C_3) alkyl and phenyl;


5 R^{22} and R^{23} are independently selected from hydrogen, hydroxy, halo, amino, carboxy, carboxy (C_1-C_6) alkyl, (C_1-C_6) alkylamino, di- (C_1-C_6) alkylamino, (C_1-C_6) alkoxy, (C_1-C_6) alkyl-O-C(=O)-, (C_1-C_6) alkyl-O-C(=O)- (C_1-C_6) alkyl, (C_1-C_6) alkyl-C(=O)- (C_1-C_6) alkyl-C(=O)- (C_1-C_6) alkyl-O-, (C_1-C_6) alkyl-C-, (C_1-C_6) alkyl-C(=O)- (C_1-C_6) alkyl, (C_1-C_6) straight or branched alkyl, (C_3-C_7) cycloalkyl wherein one of the carbon atoms may optionally be replaced by nitrogen, oxygen or sulfur; aryl selected from phenyl and naphthyl; heteroaryl selected from indanyl, thienyl, furyl, pyridyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl, tetrazolyl and quinolyl; phenyl- (C_2-C_6) alkyl, benzhydryl and benzyl, wherein each of said aryl and heteroaryl groups and the phenyl moieties of said benzyl, phenyl- (C_2-C_6) alkyl and benzhydryl may optionally be substituted with one or two substituents independently selected from halo, nitro, (C_1-C_6) alkyl optionally substituted with from one to three fluorine atoms, (C_1-C_6) alkoxy optionally substituted with from one to three fluorine atoms, trifluoromethyl, amino, (C_1-C_6) alkylamino, (C_1-C_6) alkyl-O-C(=O), (C_1-C_6) alkyl-O-C(=O)- (C_1-C_6) alkyl, (C_1-C_6) alkyl-C(=O)-O-, (C_1-C_6) alkyl-C(=O)- (C_1-C_6) alkyl-O-, (C_1-C_6) alkyl-C(=O)-, (C_1-C_6) alkyl-C- (C_1-C_6) alkyl-, di- (C_1-C_6) alkylamino, -C(=O)NH- (C_1-C_6) alkyl, (C_1-C_6) alkyl-C(=O)-NH- (C_1-C_6) alkyl, -NHC(=O)H and -NHC(=O)- (C_1-C_6) alkyl; and wherein one of the phenyl moieties of said benzhydryl may optionally be replaced by naphthyl, thienyl, furyl or pyridyl;

or R^9 , together with the carbon to which it is attached, the nitrogen of the pyrrolidine ring, the carbon to which R^7 is attached and the carbon to which R^5 and R^6 are attached form a second pyrrolidine ring; with the proviso that when R^9 , together with the carbon to which it is attached, the nitrogen of the pyrrolidine ring, the carbon to which R^7 is attached and the carbon to which R^5 and R^6 are attached, form a second pyrrolidine ring (thus forming a bicyclic structure containing a bridgehead nitrogen), either R^{12} is absent or R^{12} is present and the nitrogen of the second pyrrolidine ring is positively charged.

8. A method of treating anxiety or depression in a mammal, comprising administering to said mammal an antianxiety effective amount or an antidepressant effective amount, respectively, of a pharmaceutical composition according to claims 1, 2, 3, 4, 5, 6, or 7.


9. A method of treating anxiety or depression in a mammal, comprising administering to said mammal: (a) a compound that exhibits activity as an anxiolytic antianxiety agent or an antidepressant, or a pharmaceutically acceptable salt thereof; and (b) a CNS-penetrant NK-1 receptor antagonist or pharmaceutically acceptable salt thereof; wherein the active agents "a" and "b" above are present in amounts that render the combination of the two agents effective in treating, respectively, anxiety or depression.

10. A method according to claim 9, wherein the NK-1 receptor antagonist or pharmaceutically acceptable salt thereof is selected from compounds of the formula I, as depicted and defined below, and their pharmaceutically acceptable salts:




- 5 wherein X¹ is hydrogen, (C₁-C₁₀) alkoxy optionally substituted with from one to three fluorine atoms or (C₁-C₁₀) alkyl optionally substituted with from one to three fluorine atoms;
- X² and X³ are independently selected from hydrogen, halo, nitro, (C₁-C₁₀) alkyl optionally substituted with from one to three fluorine atoms, (C₁-C₁₀) alkoxy optionally substituted with from one to three fluorine atoms, trifluoromethyl, hydroxy, phenyl, cyano, amino, (C₁-C₆)-alkylamino, di-(C₁-C₆)alkylamino, -C(=O)-NH-(C₁-C₆)alkyl, (C₁-C₆) alkyl-C(=O)-NH-(C₁-C₆) alkyl, hydroxy(C₁-C₄)alkyl, (C₁-C₄)alkoxy(C₁-C₄)alkyl, -NHC(=O)H and -NHC(=O)-(C₁-C₆) alkyl; and
- 10 Q is a group of the formula


002044-02E.00200




11




111




IV



V




VI



VII

OR



VIII


wherein R^1 is a radical selected from furyl, thienyl, pyridyl, indolyl, biphenyl and phenyl optionally substituted with one or two substituents independently selected from halo, (C_1-C_{10}) alkyl optionally substituted with from one to three fluorine atoms, (C_1-C_{10}) alkoxy optionally substituted with from one to three fluorine atoms, carboxy, benzyloxycarbonyl and (C_1-C_3) alkoxy-carbonyl;

5 R^{13} is selected from (C_3-C_4) branched alkyl, (C_5-C_6) branched alkenyl, (C_5-C_7) cycloalkyl, and the radicals named in the definition of R^1 ;

R^2 is hydrogen or (C_1-C_6) alkyl;

R^3 is phenyl, biphenyl, naphthyl, pyridyl, benzhydryl, thienyl or furyl, and R^3 may optionally be substituted with from one to three substituents independently selected from halo, (C_1-C_{10}) alkyl optionally substituted with from one to three fluorine atoms and (C_1-C_{10}) alkoxy optionally substituted with from one to three fluorine atoms;

Y is $(CH_2)_l$ wherein l is an integer from one to three, or Y is a group of the formula



Z is oxygen, sulfur, amino, (C_1-C_3) alkylamino or $(CH_2)_n$ wherein n is zero, one or two;

15 o is two or three;

p is zero or one;

R^4 is furyl, thienyl, pyridyl, indolyl, biphenyl, or phenyl optionally substituted with one or two substituents independently selected from halo, (C_1-C_{10}) alkyl optionally substituted with from one to three fluorine atoms, (C_1-C_{10}) alkoxy optionally substituted with from one to three fluorine atoms, carboxy, (C_1-C_3) alkoxy-carbonyl and benzyloxycarbonyl;

20 R^5 is thienyl, biphenyl or phenyl optionally substituted with one or two substituents independently selected from halo, (C_1-C_{10}) alkyl optionally substituted with from one to three fluorine atoms and (C_1-C_{10}) alkoxy optionally substituted with from one to three fluorine atoms;

X is $(CH_2)_q$ wherein q is an integer from 1 to 6, and wherein any one of the carbon-carbon single bonds in said $(CH_2)_q$ may optionally be replaced by a carbon-carbon double bond, and wherein any one of the carbon atoms of said $(CH_2)_q$ may optionally be substituted with R^8 , and wherein any one of the carbon atoms of said $(CH_2)_q$ may optionally be substituted with R^9 ;

25 m is an integer from 0 to 8, and any one of the carbon-carbon single bonds of $(CH_2)_m$ may optionally be replaced by a carbon-carbon double bond or a carbon-carbon triple bond, and any one of the carbon atoms of said $(CH_2)_m$ may optionally be substituted with R^{11} ;

30 R^6 is a radical selected from hydrogen, (C_1-C_6) straight or branched alkyl, (C_3-C_7) cycloalkyl wherein one of the carbon atoms may optionally be replaced by nitrogen, oxygen or sulfur; aryl selected from biphenyl, phenyl, indanyl and naphthyl; heteroaryl selected from thienyl,

furyl, pyridyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl, tetrazolyl and quinolyl; phenyl (C₂-C₆) alkyl, benzhydryl and benzyl, wherein each of said aryl and heteroaryl groups and the phenyl moieties of said benzyl, phenyl (C₂-C₆) alkyl and benzhydryl may optionally be substituted with one or more substituents independently selected from halo, nitro, (C₁-C₁₀) alkyl optionally substituted with from one to three fluorine atoms, (C₁-C₁₀) alkoxy optionally substituted with from one to three fluorine atoms, amino, hydroxy-(C₁-C₆)alkyl, (C₁-C₆)alkoxy-(C₁-C₆)alkyl, (C₁-C₆)-alkylamino, (C₁-C₆)alkyl-O-C(=O)-, (C₁-C₆) alkyl-O-C(=O)-(C₁-C₆)alkyl, (C₁-C₆)alkyl-C(=O)-O-, (C₁-C₆)alkyl-C(=O)-(C₁-C₆)alkyl-O-, (C₁-C₆)alkyl-C(=O)-, (C₁-C₆)alkyl-C(=O)-(C₁-C₆)alkyl-, di-(C₁-C₆)alkylamino, -C(=O)NH-(C₁-C₆)alkyl, (C₁-C₆)-alkyl-C(=O)-NH-(C₁-C₆)alkyl, -NHC(=O)H and -NHC(=O)-(C₁-C₆) alkyl; and wherein one of the phenyl moieties of said benzhydryl may optionally be replaced by naphthyl, thienyl, furyl or pyridyl;

R⁷ is hydrogen, phenyl or (C₁-C₆)alkyl;

or R⁶ and R⁷, together with the carbon to which they are attached, form a saturated carbocyclic ring having from 3 to 7 carbon atoms wherein one of said carbon atoms may optionally be replaced by oxygen, nitrogen or sulfur;

R⁸ and R⁹ are each independently selected from hydrogen, hydroxy, halo, amino, oxo (=O), nitrile, hydroxy-(C₁-C₆)alkyl, (C₁-C₆)alkoxy-(C₁-C₆)alkyl, (C₁-C₆)alkylamino, di-(C₁-C₆)alkylamino, (C₁-C₆)alkoxy, (C₁-C₆)alkyl-O-C(=O)-, (C₁-C₆)alkyl-O-C(=O)-(C₁-C₆)alkyl-, (C₁-C₆)alkyl-C(=O)-O-, (C₁-C₆)alkyl-C(=O)-(C₁-C₆)alkyl-O-, (C₁-C₆)alkyl-C(=O)-, (C₁-C₆)alkyl-C(=O)-(C₁-C₆)alkyl-, and the radicals set forth in the definition of R⁶;


R¹⁰ is NHCR¹², NHCH₂R¹², NHSO₂R¹² or one of the radicals set forth in any of the definitions of R⁶, R⁸ and R⁹;

R¹¹ is oximino (=NOH) or one of the radicals set forth in any of the definitions of R⁶, R⁸ and R⁹; and

R¹² is (C₁-C₆)alkyl, hydrogen, phenyl(C₁-C₆)alkyl or phenyl optionally substituted with (C₁-C₆) alkyl; and

with the proviso that (a) when m is 0, R¹¹ is absent, (b) neither R⁸, R⁹, R¹⁰ nor R¹¹ can form, together with the carbon to which it is attached, a ring with R⁷, (c) when Q is a group of the formula VIII, R⁸ and R⁹ cannot be attached to the same carbon atom, and (d) when R⁸ and R⁹ are attached to the same carbon atom, then either each of R⁸ and R⁹ is independently selected from hydrogen, fluoro, (C₁-C₆) alkyl, hydroxy-(C₁-C₆)alkyl and (C₁-C₆)alkoxy-(C₁-C₆)alkyl, or R⁸ and R⁹, together with the carbon to which they are attached, form a (C₃-C₆) saturated carbocyclic ring that forms a spiro compound with the nitrogen-containing ring to which they are attached.

11. A method according to ~~claim~~-9, wherein the NK-1 receptor antagonist or pharmaceutically acceptable salt thereof is selected from compounds of the formula XVIII, as depicted and defined below, and their pharmaceutically acceptable salts:



wherein R is halo (C₁-C₈)alkyl, halo (C₂-C₈)alkenyl, halo (C₂-C₈)alkynyl or halo (C₁-C₈)alkyl substituted by hydroxy or (C₁-C₈)alkoxy; R' is hydrogen, halo or (C₁-C₆)alkoxy; or



R and R', together with the two carbon atoms shared between the benzene ring and the R and R', complete a fused (C₄-C₈)cycloalkyl wherein one carbon atom is optionally replaced by oxygen and wherein one or two of the carbon atoms are optionally substituted by up to five substituents selected from halo, (C₁-C₆)alkyl and halo (C₁-C₆)alkyl;

X is (C₁-C₆)alkoxy, halo (C₁-C₆)alkoxy, phenoxy or halo; and

Ar is phenyl optionally substituted by halo.


12. A method according to claim 11, wherein the NK-1 receptor antagonist is administered in an amount ranging from about 5 mg per day to about 200 mg per day.

13. A method according to claim 9, wherein the NK-1 receptor antagonist or pharmaceutically acceptable salt thereof is selected from compounds of the formula IXa or IXb, as depicted and defined below, and their pharmaceutically acceptable salts:




wherein A is a ring system selected from phenyl, naphthyl, thienyl, quinoliny and indoliny, and wherein the side chain containing NR²R³ is attached to a carbon atom of ring system A;


W is hydrogen, (C₁-C₆)alkyl optionally substituted with from one to three fluorine atoms, -S(O)_v-(C₁-C₆) alkyl wherein v is zero, one or two, halo, benzyloxy or (C₁-C₆)alkoxy optionally substituted with from one to three fluorine atoms;




V




XI




XII




XIII



XIV




XV



XVI

and



XVII

wherein R^6 and R^{10} are independently selected from furyl, thienyl, pyridyl, indolyl, biphenyl and

phenyl, wherein said phenyl may optionally be substituted with one or two substituents independently selected from halo, (C₁-C₁₀) alkyl optionally substituted with from one to three fluorine atoms, (C₁-C₁₀) alkoxy optionally substituted with from one to three fluorine atoms, carboxy, benzyloxycarbonyl and (C₁-C₃) alkoxy-carbonyl;


5 R⁴ is (C₁-C₆) alkyl or phenyl;

R⁷ is selected from (C₃-C₄) branched alkyl, (C₅-C₆) branched alkenyl, (C₅-C₇) cycloalkyl, and the radicals named in the definition of R⁶;

R⁸ is hydrogen or (C₁-C₆) alkyl;

10 R⁹ and R¹⁹ are independently selected from phenyl, biphenyl, naphthyl, pyridyl, benzhydryl, thienyl and furyl, and R⁹ and R¹⁹ may optionally be substituted with from one to three substituents independently selected from halo, (C₁-C₁₀) alkyl optionally substituted with from one to three fluorine atoms and (C₁-C₁₀) alkoxy optionally substituted with from one to three fluorine atoms;

Y is (CH₂)_l wherein l is an integer from one to three, or Y is a group of the formula



15

Z is oxygen, sulfur, amino, (C₁-C₃)alkylamino or (CH₂)_n wherein n is zero, one or two;

x is zero, one or two;

y is zero, one or two;

z is three, four or five;

20

o is two or three;

p is zero or one;

r is one, two or three;

the ring containing (CH₂)_z may contain from zero to three double bonds, and one of the carbon atoms of (CH₂)_z may optionally be replaced by oxygen, sulfur or nitrogen;

25

R¹¹ is thienyl, biphenyl or phenyl optionally substituted with one or two substituents independently selected from halo, (C₁-C₁₀) alkyl optionally substituted with from one to three fluorine atoms and (C₁-C₁₀) alkoxy optionally substituted with from one to three fluorine atoms;

30 X is (CH₂)_q wherein q is an integer from 1 to 6, and wherein any one of the carbon-carbon single bonds in said (CH₂)_q may optionally be replaced by a carbon-carbon double bond, and wherein any one of the carbon atoms of said (CH₂)_q may optionally be substituted with R¹⁴, and wherein any one of the carbon atoms of said (CH₂)_q may optionally be substituted with R¹⁵;

m is an integer from 0 to 8, and any one of the carbon-carbon single bonds of (CH₂)_m, wherein both carbon atoms of such bond are bonded to each other and to another carbon atom

of the $(CH_2)_m$ chain, may optionally be replaced by a carbon-carbon double bond or a carbon-carbon triple bond, and any one of the carbon atoms of said $(CH_2)_m$ may optionally be substituted with R^{17} ;

R^{12} is a radical selected from hydrogen, (C_1-C_6) straight or branched alkyl, (C_3-C_7) cycloalkyl wherein one of the carbon atoms may optionally be replaced by nitrogen, oxygen or sulfur; aryl selected from biphenyl, phenyl, indanyl and naphthyl; heteroaryl selected from thienyl, furyl, pyridyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl, tetrazolyl and quinolyl; phenyl- (C_2-C_6) alkyl, benzhydryl and benzyl, wherein the point of attachment on R^{12} is a carbon atom unless R^{12} is hydrogen, and wherein each of said aryl and heteroaryl groups and the phenyl moieties of said benzyl, phenyl- (C_2-C_6) alkyl and benzhydryl may optionally be substituted with one or more substituents independently selected from halo, nitro, (C_1-C_{10}) alkyl optionally substituted with from one to three fluorine atoms, (C_1-C_{10}) alkoxy optionally substituted with from one to three fluorine atoms, amino, hydroxy- (C_1-C_6) alkyl, (C_1-C_6) alkoxy- (C_1-C_6) alkyl, (C_1-C_6) alkylamino, (C_1-C_6) alkyl-O-C(=O)-, (C_1-C_6) alkyl-O-C(=O)- (C_1-C_6) alkyl, (C_1-C_6) alkyl-C(=O)-O-, (C_1-C_6) alkyl-C(=O)- (C_1-C_6) alkyl-O-, (C_1-C_6) alkyl-C(=O)-, (C_1-C_6) alkyl-C(=O)-, (C_1-C_6) alkyl-, di- (C_1-C_6) alkylamino, -C(=O)-NH- (C_1-C_6) alkyl, (C_1-C_6) alkyl-C(=O)-NH- (C_1-C_6) alkyl, -NHC(=O)H and -NHC(=O)- (C_1-C_6) alkyl; and wherein one of the phenyl moieties of said benzhydryl may optionally be replaced by naphthyl, thienyl, furyl or pyridyl;

R^{13} is hydrogen, phenyl or (C_1-C_6) alkyl; or R^{12} and R^{13} , together with the carbon to which they are attached, form a saturated carbocyclic ring having from 3 to 7 carbon atoms wherein one of said carbon atoms that is neither the point of attachment of the spiro ring nor adjacent to such point of attachment may optionally be replaced by oxygen, nitrogen or sulfur;

R^{14} and R^{15} are each independently selected from hydrogen, hydroxy, halo, amino, oxo (=O), cyano, hydroxy- (C_1-C_6) alkyl, (C_1-C_6) alkoxy- (C_1-C_6) alkyl, (C_1-C_6) alkylamino, di- (C_1-C_6) alkylamino, (C_1-C_6) alkoxy, -C(=O)-OH, (C_1-C_6) alkyl-O-C(=O)-, (C_1-C_6) alkyl-O-C(=O)- (C_1-C_6) alkyl, (C_1-C_6) alkyl-C(=O)-O-, (C_1-C_6) alkyl-C- (C_1-C_6) alkyl-O-, (C_1-C_6) alkyl-C(=O)-, (C_1-C_6) alkyl-C(=O)- (C_1-C_6) alkyl-, and the radicals set forth in the definition of R^{12} ;


R^{16} is NHC(=O) R^{18} , $NHCH_2R^{18}$, SO_2R^{18} , CO_2H or one of the radicals set forth in any of the definitions of R^{12} , R^{14} and R^{15} ;

R^{17} is oximino (=NOH) or one of the radicals set forth in any of the definitions of R^{12} , R^{14} and R^{15} ; and

R^{18} is (C_1-C_6) alkyl, hydrogen, phenyl or phenyl (C_1-C_6) alkyl; with the proviso that (a) when m is 0, one of R^{16} and R^{17} is absent and the other is hydrogen, (b) when R^3 is a group of the formula XVI, R^{14} and R^{15} cannot be attached to the same carbon atom, (c) when R^{14} and R^{15} are attached to the same carbon atom, then either each of R^{14} and R^{15} is independently selected from hydrogen, fluoro, (C_1-C_6) alkyl, hydroxy- (C_1-C_6) alkyl

- and (C₁-C₆)alkoxy-(C₁-C₆)alkyl, or R¹⁴ and R¹⁵, together with the carbon to which they are attached, form a (C₃-C₆) saturated carbocyclic ring that forms a spiro compound with the nitrogen-containing ring to which they are attached; (d) R¹² and R¹³ can not both be hydrogen, and (e) when R¹⁴ or R¹⁵ is attached to a carbon atom of X or (CH₂)_y that is adjacent to the ring nitrogen, then R¹⁴ or R¹⁵, respectively, must be a substituent wherein the point of attachment is a carbon atom.

14. A method according to claim 9, wherein the NK-1 receptor antagonist or pharmaceutically acceptable salt thereof is selected from compounds of the formula XIX, as depicted and defined below, and their pharmaceutically acceptable salts:



wherein

W is methylene, ethylene, propylene, vinylene, -CH₂-O-, -O-CH₂-, -CH₂-S- or -S-CH₂-;

R¹, R² and R³ are independently hydrogen, (C₁-C₃) alkyl, (C₁-C₃) alkoxy or halo (C₁-C₃) alkyl, provided that when W is methylene, both R² and R³ are not hydrogen;


X is halo, (C₁-C₃) alkoxy, (C₁-C₃) alkoxy or (C₁-C₃) alkenyl;

Y is imino or oxy;

Q is oxygen or sulfur; and


T is (2S,3S)-2-diphenylmethylquinuclidin-3-yl, (2S,3S)-2-phenylpiperdin-3-yl or (2S,3S)-2-diphenylmethyl-1-azanorbornan-3-yl.

15. A method according to claim 9, wherein the NK-1 receptor antagonist or pharmaceutically acceptable salt thereof is selected from compounds of the formula XX, as depicted and defined below, and their pharmaceutically acceptable salts:



wherein R^1 is phenyl optionally substituted with one or more substituents, preferably with from one to three substituents, independently selected from hydrogen, halo, nitro, (C_1-C_{10}) alkyl optionally substituted with from one to three fluorine atoms, (C_1-C_{10}) alkoxy optionally substituted with from one to three fluorine atoms, trifluoromethyl, hydroxy, phenyl, cyano, amino, (C_1-C_6) -alkylamino, di- (C_1-C_6) -alkylamino, $-C(=O)-NH-(C_1-C_6)$ alkyl, (C_1-C_6) alkyl- $C(=O)-NH-(C_1-C_6)$ alkyl, hydroxy (C_1-C_4) alkyl, $-NHC(=O)H$, $-NHC(=O)-(C_1-C_6)$ alkyl, (C_1-C_4) alkoxy (C_1-C_4) alkyl, $-S(O)_v-(C_1-C_{10})$ -alkyl wherein v is zero, one or two, $-S(O)_v$ -aryl wherein v is zero, one or two, $-O$ -aryl, $-SO_2NR^4R^5$ wherein each of R^4 and R^5 is, independently, (C_1-C_6) alkyl, or R^4 and R^5 , together with the nitrogen to which they are attached, form a saturated ring containing one nitrogen and from 3 to 6 carbons, $(SO_2-(C_1-C_{10})$ alkyl) $((C_1-C_{10})$ alkyl)N wherein one or both of the alkyl moieties may optionally be substituted with from one to three fluorine atoms, $-N(SO_2-(C_1-C_{10})$ alkyl) $_2$ and $(SO_2$ -aryl) $((C_1-C_{10})$ alkyl)N; and wherein the aryl moieties of said $-S(O)_v$ -aryl, $-O$ -aryl and $(SO_2$ -aryl) $((C_1-C_{10})$ alkyl)N are independently selected from phenyl and benzyl and may optionally be substituted with from one to three substituents independently selected from (C_1-C_4) alkyl, (C_1-C_4) alkoxy and halo;

or R^1 is phenyl substituted with a group having the formula



wherein a is 0, 1 or 2 and the asterisk represents a position meta to the point of attachment of R^1 ;

R^2 is selected from (C_1-C_6) straight or branched alkyl, (C_3-C_7) cycloalkyl wherein one of the carbon atoms may optionally be replaced by nitrogen, oxygen or sulfur; aryl selected from

biphenyl, phenyl, indanyl and naphthyl; heteroaryl selected from thienyl, furyl, pyridyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl, tetrazolyl and quinolyl; phenyl (C₂-C₆) alkyl, benzhydryl and benzyl, wherein each of said aryl and heteroaryl groups and the phenyl moieties of said benzyl, phenyl (C₂-C₆) alkyl and benzhydryl may optionally be substituted with one or more substituents, preferably with from one to three substituents, independently selected from halo, nitro, (C₁-C₁₀) alkyl optionally substituted with from one to three fluorine atoms, (C₁-C₁₀) alkoxy optionally substituted with from one to three fluorine atoms, amino, hydroxy-(C₁-C₆)alkyl, (C₁-C₆)alkoxy-(C₁-C₆)alkyl, (C₁-C₆)-alkylamino, (C₁-C₆)alkyl-O-C(=O)-, (C₁-C₆)alkyl-O-C(=O)-(C₁-C₆)alkyl, (C₁-C₆)alkyl-C(=O)-O-, (C₁-C₆)alkyl-C-(C₁-C₆)alkyl-O-, (C₁-C₆)alkyl-C(=O)-, (C₁-C₆)alkyl-C-(C₁-C₆)alkyl-, di-(C₁-C₆)alkylamino, -C(=O)NH-(C₁-C₆)alkyl, (C₁-C₆)-alkyl-C(=O)-NH-(C₁-C₆)alkyl, -NHC(=O)H and -NHC(=O)-(C₁-C₆) alkyl; and wherein one of the phenyl moieties of said benzhydryl may optionally be replaced by naphthyl, thienyl, furyl or pyridyl;

m is an integer from 0 to 8, and any one of the carbon-carbon single bonds of (CH₂)_m, wherein both carbon atoms of such bond are bonded to each other and to another carbon atom in the (CH₂)_m chain, may optionally be replaced by a carbon-carbon double bond or a carbon-carbon triple bond, and any one of the carbon atoms of said (CH₂)_m may optionally be substituted with R⁴;


R³ is selected from NHC(=O)R⁸, NHCH₂R⁸, SO₂R⁸, AR⁵, CO₂H and the radicals set forth in the definitions of R², R⁶ and R⁷;

A is CH₂, nitrogen, oxygen, sulfur or carbonyl;

R⁸ is (C₁-C₆)alkyl, hydrogen, phenyl or phenyl (C₁-C₆)alkyl;

R⁴ is selected from oximino (=NOH) and the radicals set forth in the definitions of R², R⁶ and R⁷;

R⁵ is a monocyclic or bicyclic heterocycle selected from the group consisting of pyrimidinyl, benzoxazolyl, 2,3-dihydro-3-oxobenzisoxazol-2-yl, morpholin-1-yl, thiomorpholin-1-yl, benzofuranyl, benzothienyl, indolyl, isoindolyl, isoquinolyl, furyl, pyridyl, isothiazolyl, oxazolyl, triazolyl, tetrazolyl, quinolyl, thiazolyl, thienyl, and groups of the formulae



wherein B and D are selected from carbon, oxygen and nitrogen, and at least one of B and D is other than carbon; E is carbon or nitrogen; n is an integer from 1 to 5; any one of the carbon atoms of said (CH₂)_n and (CH₂)_{n+1} may be optionally substituted with (C₁-C₆)alkyl or (C₂-C₆) spiroalkyl; and either any one pair of the carbon atoms of said (CH₂)_n and (CH₂)_{n+1} may be bridged by a one or two carbon atom linkage, or any one pair of adjacent carbon atoms of said

(CH₂)_n and (CH₂)_{n+1} may form, together with from one to three carbon atoms that are not members of the carbonyl containing ring, a (C₃-C₅) fused carbocyclic ring;


X is (CH₂)_q wherein q is two or three and wherein one of the carbon-carbon single bonds in said (CH₂)_q may optionally be replaced by a carbon-carbon double bond, and wherein any one of the carbon atoms of said (CH₂)_q may optionally be substituted with R⁶, and wherein any one of the carbon atoms of said (CH₂)_q may optionally be substituted with R⁷;

R⁶ and R⁷ are independently selected from hydrogen, hydroxy, halo, amino, oxo (=O), cyano, hydroxy-(C₁-C₆)alkyl, (C₁-C₆)alkoxy-(C₁-C₆)alkyl, (C₁-C₆)alkylamino, di-(C₁-C₆)alkylamino, (C₁-C₆)alkoxy, -C(=O)-OH, (C₁-C₆)alkyl-O-C(=O)-, (C₁-C₆)alkyl-O-C(=O)-(C₁-C₆)alkyl, (C₁-C₆)alkyl-C(=O)-O-, (C₁-C₆)alkyl-C(=O)-(C₁-C₆)alkyl-O-, (C₁-C₆)alkyl-C-, (C₁-C₆)alkyl-C(=O)-(C₁-C₆)alkyl- and the radicals set forth in the definition of R²; and

Y is (CH₂)_z wherein z is zero or one;

with the proviso that: (a) when A is -(CH₂)- or carbonyl, R⁵ cannot be furyl, pyridyl, isothiazolyl, oxazolyl, triazolyl, tetrazolyl, quinolyl, thiazolyl or thienyl; (b) when m is zero, one of R³ and R⁴ is absent and the other is hydrogen; and (c) when R⁶ or R⁷ is attached to a carbon atom of X that is adjacent to the ring nitrogen, then R⁶ or R⁷, respectively, must be a substituent wherein the point of attachment is a carbon atom.

16. A method according to claim 9, wherein the NK-1 receptor antagonist or pharmaceutically acceptable salt thereof is selected from compounds of the formula XXI, as depicted and defined below, and their pharmaceutically acceptable salts:



wherein R¹ is selected from hydrogen, (C₁-C₆) straight or branched alkyl, (C₃-C₇) cycloalkyl wherein one of the carbon atoms may optionally be replaced by nitrogen, oxygen or sulfur; aryl selected from phenyl, biphenyl, indanyl and naphthyl; heteroaryl selected from thienyl, furyl, pyridyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl, tetrazolyl and quinolyl; phenyl (C₂-C₆) alkyl, benzhydryl and benzyl, wherein each of said aryl and heteroaryl groups and the phenyl moieties of said benzyl, phenyl (C₂-C₆) alkyl and benzhydryl may optionally be substituted with one or more substituents independently selected from halo, nitro, (C₁-C₆) alkyl optionally substituted with from one to three fluorine atoms, (C₁-C₆) alkoxy, amino, trihaloalkoxy (e.g., trifluoromethoxy), (C₁-C₆)alkylamino, (C₁-C₆)alkyl-O-C(=O)-, (C₁-C₆)alkyl-O-C(=O)-(C₁-C₆)alkyl, (C₁-C₆)alkyl-C(=O)-O-, (C₁-C₆)alkyl-C-, (C₁-C₆)alkyl-O-, (C₁-C₆)alkyl-C(=O)-, (C₁-C₆)alkyl-C(=O)-, (C₁-C₆)alkyl-, di-(C₁-C₆)alkylamino, -C(=O)NH-(C₁-C₆)alkyl, (C₁-C₆)alkyl-C(=O)-NH-(C₁-C₆)alkyl-,

-NHC(=O)H and -NHC(=O)-(C₁-C₆) alkyl; and wherein one of the phenyl moieties of said benzhydryl may optionally be replaced by naphthyl, thienyl, furyl or pyridyl;

R³ is aryl selected from phenyl and naphthyl; heteroaryl selected from indanyl, thienyl, furyl, pyridyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl, tetrazolyl and quinolyl; and
 5 cycloalkyl having 3 to 7 carbon atoms wherein one of said carbon atoms may optionally be replaced by nitrogen, oxygen or sulfur; wherein each of said aryl and heteroaryl groups may optionally be substituted with one or more substituents, and said (C₃-C₇) cycloalkyl may optionally be substituted with one or two substituents, each of said substituents being independently selected from halo, nitro, (C₁-C₆) alkyl optionally substituted with from one to three fluorine
 10 atoms, (C₁-C₆) alkoxy, amino, phenyl, trihaloalkoxy (e.g., trifluoromethoxy), (C₁-C₆) alkylamino, -C(=O)-NH-(C₁-C₆)alkyl, (C₁-C₆)alkyl-C(=O)-, -C-O-(C₁-C₆)alkyl, -C(=O)H, -CH₂OR¹³, NH(C₁-C₆)alkyl-, -NHC(=O)H, -NR²⁴C-(C₁-C₆)alkyl and -NHC(=O)-(C₁-C₆)alkyl;


one of R⁵ and R⁶ is hydrogen and the other is selected from hydroxymethyl, hydrogen, (C₁-C₃)alkyl, (C₁-C₈)acyloxy(C₁-C₃)alkyl, (C₁-C₈)alkoxymethyl and benzyloxymethyl;

15 R⁷ and R⁸ are independently selected from hydrogen, (C₁-C₃)alkyl and phenyl;

R⁹ is selected from methyl, hydroxymethyl, HC(=O)-, R¹⁴R¹⁵NCO₂CH₂-, R¹⁶OCO₂CH₂-, (C₁-C₄)alkyl-CO₂CH₂-, -CONR¹⁷R¹⁸, R¹⁷R¹⁸NCO₂-, R¹⁹OCO₂-, C₆H₅CH₂CO₂CH₂-, C₆H₅CO₂CH₂-, (C₁-C₄)alkyl-CH(OH)-, C₆H₅CH(OH)-, C₆H₅CH₂CH(OH)-, CH₂halo, R²⁰SO₂OCH₂-, -CO₂R¹⁶ and R²¹CO₂-;

20 R¹⁰ and R¹¹ are independently selected from hydrogen, (C₁-C₃) alkyl and phenyl;

R¹² is hydrogen, benzyl or a group of the formula



wherein m is an integer from zero to twelve, and any one of the carbon-carbon single bonds of (CH₂)_m may optionally be replaced by a carbon-carbon double or triple bond, and any
 25 one of the carbon atoms of (CH₂)_m may optionally be substituted with R²³ (as indicated by the slanted line to R²³ which intersects the horizontal line to (CH₂)_m in the above figure);

R¹³, R¹⁴, R¹⁵, R¹⁶, R¹⁷, R¹⁸, R¹⁹, R²⁰, R²¹ and R²⁴ are independently selected from hydrogen, (C₁-C₃)alkyl and phenyl;

R²² and R²³ are independently selected from hydrogen, hydroxy, halo, amino, carboxy, carboxy(C₁-C₆)alkyl, (C₁-C₆)alkylamino, di-(C₁-C₆)alkylamino, (C₁-C₆)alkoxy, (C₁-C₆)alkyl-O-C(=O)-, (C₁-C₆)alkyl-O-C(=O)-(C₁-C₆)alkyl, (C₁-C₆)alkyl-C(=O)- (C₁-C₆)alkyl-C(=O)-(C₁-C₆)alkyl-O-, (C₁-C₆)alkyl-C-, (C₁-C₆)alkyl-C(=O)-(C₁-C₆)alkyl, (C₁-C₆) straight or branched alkyl, (C₃-C₇) cycloalkyl wherein one of the carbon atoms may optionally be replaced by nitrogen, oxygen or sulfur; aryl selected from phenyl and naphthyl; heteroaryl selected from indanyl, thienyl, furyl,
 30 pyridyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl, tetrazolyl and quinolyl; phenyl-(C₂-

or R⁹, together with the carbon to which it is attached, the nitrogen of the pyrrolidine ring, the carbon to which R⁷ is attached and the carbon to which R⁵ and R⁶ are attached form a second pyrrolidine ring; with the proviso that when R⁹, together with the carbon to which it is attached, the nitrogen of the pyrrolidine ring, the carbon to which R⁷ is attached and the carbon to which R⁵ and R⁶ are attached, form a second pyrrolidine ring (thus forming a bicyclic structure containing a bridgehead nitrogen), either R¹² is absent or R¹² is present and the nitrogen of the second pyrrolidine ring is positively charged.